Comparative analysis of the efficacy and side effects of DaliRasen and LeboRasen

Daridorexant (Daridorexant) and Leborexant (Lemborexant) are new sleep-regulating drugs, belonging to the orexin receptor antagonist (ORAs) class, used to treat adult insomnia. Although both reduce arousal signals and promote sleep by antagonizing Orexin receptors in the brain, there are still certain differences in pharmacological properties, clinical efficacy and side effects. The following is a comparative analysis from multiple angles.

1. Mechanism of action and pharmacological differences

DaliRasen and LeboRasen both inhibit the binding of Orexin-A and Orexin-B to their receptors and reduce the transmission of arousal signals, thereby helping patients fall asleep and maintain sleep. DaliRazen is a dual receptor antagonist (DORA), which mainly targets the OX1R and OX2R receptors. It has a more balanced effect on sleep maintenance and has a moderate half-life, helping to reduce daytime sleepiness. Leborexan is also DORA, but its pharmacokinetics show a slightly longer half-life and a more significant improvement in sleep continuation and nighttime awakening, but it may also increase the risk of drowsiness the next day.

2. Comparison of clinical efficacy

In randomized controlled trials, DaliRasen performed well in improving sleep onset latency (Sleep Onset Latency, SOL) and prolonging total sleep time (Total Sleep Time, TST). Studies have shown that DaliRasen can significantly improve the patient's sleep efficiency within 1 week of taking it, and is also effective in maintaining deep sleep and reducing the number of nighttime awakenings. In contrast, Leborexan has a more prominent effect on controlling nighttime awakenings, but is slightly less effective in improving the speed of falling asleep. Overall, both can effectively improve patients' subjective sleep scores and daytime functional performance, but DaliRasen has more obvious advantages in reducing next-day sleepiness.

3. Side Effects and Safety Analysis

Both Dalibrasen and Lebrasen are relatively safe sleep drugs, but their side effects vary. Common side effects include headache, dry mouth, dizziness and drowsiness. Due to its moderate half-life, DaliRazen has a mild impact on cognitive function the next day, with occasional slight dizziness or fatigue. In terms of side effects of Leborex, patients are more likely to experience next-day drowsiness, decreased concentration, and occasional mild sleepwalking or sleep-related behavioral disorders. Therefore, for patients who require efficient next-day wakefulness, DaliRasen may be more suitable.

4. Individualized Selection and Clinical Application

Clinical selection should be based on the patient's insomnia type, occupational requirements and past medication history. If the patient's main problem is difficulty falling asleep and needs to stay awake the next day, Daliramex may be better; and if the patient wakes up frequently at night, Leborexan may be more suitable in terms of prolonging the deep sleep period and reducing awakenings. In addition, both patients need to pay attention to dosage adjustment in patients with abnormal liver function, and avoid taking them with central depressant drugs or alcohol.

In summary, both dalirasin and leboraxin are effective orexin receptor antagonists that can improve sleep onset and sleep maintenance in adult patients with insomnia, but there are differences in pharmacokinetics, risk of side effects and clinical adaptability. DaliRasen has a moderate half-life and a low risk of drowsiness the next day, making it suitable for patients who have difficulty falling asleep; LebaRasen has a significant effect in controlling nighttime awakenings, but has a slightly higher risk of drowsiness the next day. Clinical application should be based on the patient's specific conditions, rational selection of drugs and attention to safe medication management.

Reference materials:https://www.drugs.com/